Clinical trials
ARDS (Moderate or Severe) clinical trials
Below are recruiting ards (moderate or severe) clinical trials, each written for real people, not researchers. We’re tracking 1,471 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT07540312Recruiting
Compression System for Moderate to Severe Irritable Bowel Syndrome
This trial tests a wearable compression device designed to help people with moderate to severe irritable bowel syndrome (IBS). The device applies variable pressure to the abdomen and may help reduce symptoms like abdominal pain, bloating, and bowel irregularities.
Kissimmee, FloridaAges 18–60 - NCT07528781Recruiting
New 3D Ultrasound Method for Measuring Heart Valve Leakage
This study tests a new way to measure leakage in the mitral valve (a valve in your heart) using advanced 3D ultrasound. If you have moderate or severe mitral valve leakage, this research may help doctors better understand and treat the condition.
Badalona, BarcelonaAges 18–95 - NCT07532486Recruiting
Guselkumab dosing study for moderate-to-severe psoriasis
This study tests whether a higher dose of guselkumab (a biologic medicine) given less frequently works as well as the standard dose for treating moderate-to-severe plaque psoriasis. The goal is to find a dosing schedule that is both effective and convenient for patients.
Hangzhou, ZhejiangAges 18 years+ - NCT07513181RecruitingPhase 2
Testing ATH-063 for Hard-to-Treat Ulcerative Colitis
This study tests a new drug called ATH-063 to see if it can help people with moderate-to-severe ulcerative colitis (a condition causing inflammation and bleeding in the colon) who haven't responded well to previous biologic treatments. The goal is to find out if this new drug is safe and effective.
Miami, FloridaAges 18–75 - NCT07499232RecruitingPhase 3
Guselkumab vs Risankizumab for Crohn's disease
This trial compares two drugs, guselkumab and risankizumab, to see which works better for people with moderate-to-severe Crohn's disease. Both are given as injections and aim to reduce inflammation in the gut.
Dothan, AlabamaAges 18 years+ - NCT07503652RecruitingPhase 4
Xeligekimab for moderate to severe palmoplantar pustulosis
This study tests a new drug (Xeligekimab) for people with moderate to severe palmoplantar pustulosis — a condition causing painful blisters on the hands and feet. It may be an option if other treatments haven't worked well.
ShenyangAges 18–75 - NCT06765005RecruitingPhase 1/Phase 2
Study of MG-K10 for Teens with Moderate to Severe Eczema
This study tests a new injectable medication called MG-K10 for teens with moderate to severe eczema that hasn't been well controlled with creams. The goal is to see if it can safely reduce inflammation and improve skin symptoms.
Hangzhou, ZhejiangAges 12–18 - NCT07489885RecruitingPhase 2
Study of D-2570 for moderate to severe plaque psoriasis
This trial tests an experimental drug, D-2570, for people with moderate to severe plaque psoriasis. It aims to see if the medication can safely improve skin symptoms.
Birmingham, AlabamaAges 18–70 - NCT07491900RecruitingPhase 1
Study of HB2198 for lupus with moderate to severe symptoms
This trial tests a new drug called HB2198 to see if it can help people with moderate to severe lupus. It may be an option for those whose current treatments haven't worked well enough.
BrisbaneAges 18–65 - NCT07489573RecruitingPhase 4
Study of secukinumab for Chinese adults with moderate-to-severe HS
This study tests if a drug called secukinumab (a self-injected biologic) is safe and effective for adults with moderate-to-severe hidradenitis suppurativa (HS) in China. It may help reduce the number of painful HS lesions.
Guangzhou, GuangdongAges 18 years+ - NCT07483372RecruitingPhase 1
SC101 injection for resistant hypertension with kidney disease
This early-phase trial tests an injection called SC101 into the fat around your kidney. It aims to help lower blood pressure in people whose hypertension is poorly controlled despite multiple medications and who have moderate to severe chronic kidney disease.
Suzhou, JiangsuAges 18–65 - NCT07477990RecruitingPhase 3
Testing a digital device for anxiety treatment
This trial is testing a digital device called Aurora that helps treat moderate to severe anxiety. It compares the device to standard anxiety medications, so you may receive either the device or a pill. The goal is to see if the device can work as well as medication without the side effects.
Mexico City, Mexico CityAges 18–65 - NCT07474792RecruitingPhase 2
Study of ORKA-002 for moderate-to-severe plaque psoriasis
This trial tests an investigational drug called ORKA-002 for people with moderate-to-severe plaque psoriasis. It aims to see how well different doses work and if they are safe. You may qualify if your psoriasis covers at least 10% of your body or if it has not responded well enough to other treatments.
Birmingham, AlabamaAges 18–79 - NCT07476313Enrolling by invitation
Testing a new home sleep system for moderate to severe sleep apnea
This study tests a home sleep testing system called SleepView+ in people who have already been scheduled for an overnight sleep lab study. If you have moderate to severe obstructive sleep apnea, this device might offer a more convenient way to monitor your sleep at home.
Redwood City, CaliforniaAges 12 years+ - NCT07463183RecruitingPhase 2
Study of MK-8690 for moderate to severe ulcerative colitis
This trial tests an investigational drug called MK-8690 for people with moderate to severe ulcerative colitis (UC) who haven't responded well to other treatments or can't tolerate them. The study aims to see if the drug can help control UC symptoms safely.
Anaheim, CaliforniaAges 18–75 - NCT07467564Recruiting
Does Dupilumab help anxiety and depression in eczema?
This study looks at whether Dupilumab (a treatment for moderate-to-severe eczema) can also help improve symptoms of anxiety and depression. It is for people with eczema who also have these mood symptoms and are about to start Dupilumab.
DohaAges 12 years+ - NCT07464587RecruitingPhase 3
Inhaled study drug for moderate to severe copd
This trial tests an inhaled medication (given through a nebulizer) to see how well it improves breathing and quality of life in people with moderate-to-severe COPD. It may help reduce symptoms and flare-ups, but will require regular visits and lung function tests.
Chizhou, AnhuiAges 40–80 - NCT06749587Recruiting
Gel filler for under-eye hollows in Chinese adults
This study tests a gel filler injected under the eyes to improve hollows or volume loss in Chinese adults.
GuangzhouAges 18 years+ - NCT06030076Recruiting
Switching to tildrakizumab for moderate to severe psoriasis
This trial is for adults with moderate to severe plaque psoriasis who are currently on a biologic treatment (like Humira, Stelara, or Cosentyx) and are switching to tildrakizumab. It looks at how your quality of life and symptoms change after the switch.
Graz, StyriaAges 18 years+ - NCT07441395RecruitingPhase 2
Study of soquelitinib for moderate to severe eczema
This trial tests an experimental pill called soquelitinib for people with moderate to severe eczema (atopic dermatitis). It aims to see if the drug can reduce symptoms like itching and skin inflammation.
South San Francisco, CaliforniaAges 18 years+ - NCT07438496RecruitingPhase 3
Study of nipocalimab for moderate to severe lupus
This trial tests a new medicine, nipocalimab, for adults with moderate to severe lupus. It aims to see if the drug can help control lupus symptoms and reduce disease activity.
Beverly Hills, CaliforniaAges 18–75 - NCT07442045Recruiting
Comparing combined vs single drug for ulcerative colitis
Researchers want to see if taking two medications together (upadacitinib and vedolizumab) works better than taking just upadacitinib alone for people with moderate to severe ulcerative colitis. This is a real-world study, meaning it looks at patients being treated in normal medical practice.
Foshan, GuangdongAges 18 years+ - NCT07427017RecruitingPhase 2
Selenium for Ulcerative Colitis Patients on Biologics
This trial tests whether taking selenium supplements can help people with moderate to severe ulcerative colitis that is being treated with advanced therapies (biologics). The goal is to see if selenium can improve symptoms and reduce inflammation.
Chicago, IllinoisAges 18–85 - NCT06815380Recruiting
Study on lebrikizumab for people with atopic dermatitis
This study looks at how lebrikizumab (Ebglyss) affects daily life and skin symptoms in adults with moderate-to-severe eczema. You may join if your doctor has prescribed this medication as part of your regular care.
Aarhus, DenmarkAges 18 years+
Hear when a new ARDS (Moderate or Severe) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for ards (moderate or severe)?
- Yes. Clin2 currently lists 1,471 recruiting ards (moderate or severe) studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a ards (moderate or severe) trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a ards (moderate or severe) trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.